Abstract:Primary osteoporosis is closely linked to hormone deficiency, which disrupts the balance of bone remodeling. It affects postmenopausal women but also significantly impacts older men. Estrogen can promote the production of osteoprotegerin, a decoy receptor for RANKL, thereby preventing RANKL from activating osteoclasts. Furthermore, estrogen promotes osteoblast survival and function via activation of the Wnt signaling pathway. Likewise, androgens play a critical role in bone metabolism, primarily through their conversion to estrogen in men. Estrogen deficiency accelerates bone resorption through a rise in pro-inflammatory cytokines (IL-1, IL-6, TNF-α) and RANKL, which promote osteoclastogenesis. In the classic genomic pathway, estrogen binds to estrogen receptors in the cytoplasm, forming a complex that migrates to the nucleus and binds to estrogen response elements on DNA, regulating gene transcription. Androgens can be defined as high-affinity ligands for the androgen receptor; their combination can serve as a ligand-inducible transcription factor. Hormone replacement therapy has shown promise but comes with associated risks and side effects. In contrast, the non-genomic pathway involves rapid signaling cascades initiated at the cell membrane, influencing cellular functions without directly altering gene expression. Therefore, the ligand-independent actions and rapid signaling pathways of estrogen and androgen receptors can be harnessed to develop new drugs that provide bone protection without the side effects of traditional hormone therapies. To manage primary osteoporosis, other pharmacological treatments (bisphosphonates, teriparatide, RANKL inhibitors, sclerostin inhibitors, SERMs, and calcitonin salmon) can ameliorate osteoporosis and improve BMD via actions on different pathways. Non-pharmacological treatments include nutritional support and exercise, as well as the dietary intake of antioxidants and natural products. The current study reviews the processes of bone remodeling, hormone actions, hormone receptor status, and therapeutic targets of primary osteoporosis. However, many detailed cellular and molecular mechanisms underlying primary osteoporosis seem complicated and unexplored and warrant further investigation.

Molecular and Cellular Mechanisms of Osteoporosis

Research and Application of Target Therapy for Osteoporosis

Molecular Mechanisms and Emerging Therapeutics for Osteoporosis

Senescent Cells: A Therapeutic Target for Osteoporosis

Mechanistic Advances in Osteoporosis and Anti-Osteoporosis Therapies.

The Development of Molecular Biology of Osteoporosis

The Molecular and Cellular Perspective on Pathophysiological Mechanisms and Treatments

Osteoporosis: Causes, Mechanisms, Treatment and Prevention: Role of Dietary Compounds

T-Cell Mediated Inflammation in Postmenopausal Osteoporosis

Advances in Pathogenesis and Therapeutic Strategies for Osteoporosis

Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics

Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review

Modulation of the Vitamin D/vitamin D Receptor System in Osteoporosis Pathogenesis: Insights and Therapeutic Approaches

Ovarian Aging and Osteoporosis.

Osteoporosis pathogenesis and treatment: existing and emerging avenues

The Quest for Osteoporosis Mechanisms and Rational Therapies: How Far We've Come, How Much Further We Need to Go

Age Related Osteoporosis: Targeting Cellular Senescence

Exercise for osteoporosis: A literature review of pathology and mechanism

Osteoporotic osseointegration: therapeutic hallmarks and engineering strategies

Oxidative Stress and Natural Antioxidants in Osteoporosis: Novel Preventive and Therapeutic Approaches

Oxidative Stress and Inflammation in Osteoporosis: Molecular Mechanisms Involved and the Relationship with microRNAs